DE3662689D1 - Thiazolidinedione derivatives, their production and use - Google Patents

Thiazolidinedione derivatives, their production and use

Info

Publication number
DE3662689D1
DE3662689D1 DE8686300220T DE3662689T DE3662689D1 DE 3662689 D1 DE3662689 D1 DE 3662689D1 DE 8686300220 T DE8686300220 T DE 8686300220T DE 3662689 T DE3662689 T DE 3662689T DE 3662689 D1 DE3662689 D1 DE 3662689D1
Authority
DE
Germany
Prior art keywords
production
thiazolidinedione derivatives
thiazolidinedione
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8686300220T
Other languages
German (de)
English (en)
Inventor
Kanji Meguro
Takeshi Fujita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11683488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3662689(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE3662689D1 publication Critical patent/DE3662689D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE8686300220T 1985-01-19 1986-01-15 Thiazolidinedione derivatives, their production and use Expired DE3662689D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP808585 1985-01-19

Publications (1)

Publication Number Publication Date
DE3662689D1 true DE3662689D1 (en) 1989-05-11

Family

ID=11683488

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8686300220T Expired DE3662689D1 (en) 1985-01-19 1986-01-15 Thiazolidinedione derivatives, their production and use
DE2001199018 Active DE10199018I2 (de) 1985-01-19 1986-01-15 Thiazolidindion-Derivate, deren Herstellung und Anwendung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE2001199018 Active DE10199018I2 (de) 1985-01-19 1986-01-15 Thiazolidindion-Derivate, deren Herstellung und Anwendung.

Country Status (28)

Country Link
US (1) US4687777A (enExample)
EP (1) EP0193256B1 (enExample)
JP (1) JPS61267580A (enExample)
KR (1) KR920010046B1 (enExample)
CN (1) CN1003934B (enExample)
AR (1) AR240698A1 (enExample)
AT (1) ATE41931T1 (enExample)
AU (1) AU572719B2 (enExample)
BR (1) BR1100325A (enExample)
CA (1) CA1277323C (enExample)
CS (1) CS407991A3 (enExample)
DE (2) DE3662689D1 (enExample)
DK (2) DK171614B1 (enExample)
ES (1) ES8705886A1 (enExample)
FI (1) FI81098C (enExample)
GR (1) GR860124B (enExample)
HK (1) HK3692A (enExample)
HU (1) HU196795B (enExample)
IE (1) IE58928B1 (enExample)
LU (1) LU90719I2 (enExample)
LV (1) LV5779B4 (enExample)
MX (1) MX9202933A (enExample)
MY (1) MY102016A (enExample)
NL (1) NL300038I2 (enExample)
NO (1) NO163857C (enExample)
PT (1) PT81859B (enExample)
SG (1) SG105691G (enExample)
ZA (1) ZA86203B (enExample)

Families Citing this family (276)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK305884A (da) * 1983-06-24 1984-12-25 Yamanouchi Pharma Co Ltd Phenoxyderivat, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
HU203330B (en) * 1987-06-10 1991-07-29 Pfizer Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them
GB8713861D0 (en) * 1987-06-13 1987-07-15 Beecham Group Plc Compounds
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US4997948A (en) * 1989-10-27 1991-03-05 American Home Products 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
DE69100282T3 (de) * 1990-02-09 2001-01-11 Pharmacia & Upjohn Co., Kalamazoo Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE69132713D1 (de) * 1990-04-27 2001-10-11 Sankyo Co Benzylidenthiazolidinderivate, ihre Herstellung und ihre Anwendung als Lipidperoxid-Inhibitoren
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
KR100249988B1 (ko) * 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP3081245B2 (ja) * 1993-09-15 2000-08-28 三共株式会社 Ｎｉｄｄｍの発症を阻止又は遅延するためのチアゾリジンジオン類の用途
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
ES2135711T4 (es) * 1994-03-08 2000-01-01 American Home Prod Derivados de tiazolidindiona como agentes antihiperglucemicos.
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
ATE238297T1 (de) * 1994-10-20 2003-05-15 Nippon Chemiphar Co Chinolinderivat
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
WO1996035688A1 (en) * 1995-05-08 1996-11-14 Nippon Chemiphar Co., Ltd. 2,4-thiazolidinedione or oxazolidinedione derivatives and hypoglycemic agent
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CA2180296C (en) * 1995-07-03 2007-01-09 Yoshio Tsujita Treatment of arteriosclerosis and xanthoma
EP0783888A1 (en) 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
JP2000511883A (ja) * 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
ATE399545T1 (de) * 1996-11-08 2008-07-15 Nippon Chemiphar Co Mittel zur verringerung der eigeweidefette
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
WO1999030739A1 (en) * 1997-12-16 1999-06-24 Sankyo Company, Limited Leukemia remedy
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
AU1740900A (en) * 1998-11-20 2000-06-13 Genentech Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AU4314000A (en) 1999-04-28 2000-11-17 Institute Of Medicinal Molecular Design. Inc. Heterocyclic carboxylic acid derivatives
HK1043113A1 (zh) * 1999-07-01 2002-09-06 Geron Corporation 端粒酶抑制劑及其使用方法
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
US7390824B1 (en) * 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
ES2156574B1 (es) * 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
EP1236719A4 (en) 1999-12-03 2003-06-25 Kyoto Pharma Ind NOVEL HETEROCYCLIC COMPOUNDS AND SALTS THEREOF, USE OF THESE COMPOUNDS IN MEDICINE
EP1741445B1 (en) 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) * 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
BR0110258A (pt) * 2000-04-25 2003-01-07 Kyorin Seiyaku Kk Cristal estável de derivado de tiazolidinadiona e processo para sua produção
WO2002024689A1 (en) * 2000-09-21 2002-03-28 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
ATE341343T1 (de) * 2000-12-26 2006-10-15 Sankyo Co Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
MXPA03006724A (es) * 2001-01-26 2003-10-24 Schering Corp Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares.
NZ526532A (en) * 2001-01-26 2005-01-28 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
DE60221798T2 (de) * 2001-01-26 2008-06-05 Schering Corp. Kombinationen von gallensäure sequestriermitteln und hemmern der sterol absorption zur behandlung von kardiovaskulären indikationen
JP4777602B2 (ja) * 2001-01-26 2011-09-21 シェーリング コーポレイション ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
JP2004517920A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション 血管状態を治療するためのステロール吸収阻害剤と血液調整剤との組合せ
PT1757606E (pt) * 2001-02-24 2009-05-26 Boehringer Ingelheim Pharma Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
ES2321815T3 (es) * 2001-04-04 2009-06-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Combinacion terapeutica que comprende inhibidores de reabsorcion e glucosa y moduladores ppar.
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
EP1382336B1 (en) * 2001-04-25 2010-09-08 Takeda Pharmaceutical Company Limited Use of the abc expression promotor pioglitazone for the treatment of arteriosclerosis obliterans
SK14452003A3 (sk) * 2001-04-26 2004-04-06 Liva, A. S. Spôsob výroby pioglitazonu ako antidiabetika
MXPA03010811A (es) * 2001-05-29 2004-02-27 Kyoto Pharma Ind Compuestos heterociclico y uso farmaceutico.
NZ530313A (en) * 2001-05-29 2005-06-24 Kyoto Pharma Ind Heterocyclic derivatives and medicinal use thereof
WO2003013609A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE411018T1 (de) * 2001-09-21 2008-10-15 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
AU2002336609B2 (en) * 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
WO2003026586A2 (en) * 2001-09-28 2003-04-03 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
CA2470075A1 (en) * 2001-12-20 2003-07-03 Teva Pharmaceutical Industries Ltd. Hydrogenation of precursors to thiazolidinedione antihyperglycemics
US20050187258A1 (en) * 2001-12-20 2005-08-25 Ben-Zion Dolitzky Hydrogenation of precursors to thiazolidinedione antihyperglycemics
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
WO2003062427A1 (fr) * 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Methode de criblage de medicaments ameliorant la resistance a l'insuline
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
DE60316152D1 (de) 2002-07-16 2007-10-18 Cadila Healthcare Ltd Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003260813A1 (en) * 2002-09-12 2004-04-30 Themis Laboratories Private Limited Improved process for preparation of thiazolidinedione derivatives
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP2006508188A (ja) * 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
WO2004087053A2 (en) 2003-03-25 2004-10-14 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004108721A1 (en) * 2003-04-01 2004-12-16 Sun Pharmaceutical Industries Limited Process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methyl]-2,4-thiazolidinedione
ES2219180B1 (es) * 2003-05-09 2006-03-01 Medichem, S.A. Compuesto intermedio util para la preparacion de pioglitazona.
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
SI1622899T1 (sl) * 2003-05-13 2007-10-31 Synthon Bv Pioglitazonsulfat, farmacevtski sestavki in njihova uporaba
US20050059708A1 (en) * 2003-05-13 2005-03-17 Karel Pospisilik Processes for making thiazolidinedione derivatives and compounds thereof
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
US7718377B2 (en) * 2003-05-29 2010-05-18 Kyoto Pharmaceutical Industries, Ltd. Insulin resistance curative and method of screening the same
KR20110117731A (ko) 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070078170A1 (en) * 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
AU2003269479A1 (en) * 2003-09-03 2005-03-16 Biocon Limited Phosphoric acid salt of 5-((4-(2-(5-ethyl-2-pyridinyl) ethoxy) phenyl) methyl)-2, 4-thiazolidinedione
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP5140881B2 (ja) * 2003-09-17 2013-02-13 要 川杉 医薬組成物
CA2544309A1 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1716144A2 (en) * 2004-02-20 2006-11-02 Synthon B.V. Processes for making pioglitazone and compounds of the processes
CN102134231B (zh) * 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
EP1731170A1 (en) * 2004-03-29 2006-12-13 Sankyo Company, Limited Therapeutic agent for diabetes containing insulin resistance improving agent
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
US20060025478A1 (en) * 2004-07-27 2006-02-02 Keisuke Inoue Medicine for prevention or treatment of diabetes
TW200608967A (en) * 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
US20070259927A1 (en) * 2004-08-26 2007-11-08 Takeda Pharmaceutical Company Limited Remedy for Diabetes
WO2006035459A1 (en) * 2004-09-28 2006-04-06 Morepen Laboratories Limited An improved process for the production of derivatives of thiozolidinediones and their precursors
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
CN101137368B (zh) * 2005-03-08 2012-05-16 奈科明有限责任公司 治疗糖尿病的罗氟司特
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
CA2601884A1 (en) * 2005-03-18 2006-09-21 Surendrakumar Satyanarayan Pandey Novel tyrosine derivatives
WO2006117654A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Processes for the preparation of pioglitazone or salts thereof
EP1905450A1 (en) * 2005-07-12 2008-04-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar gamma agonist
US20090203744A1 (en) * 2005-07-29 2009-08-13 Pande Y Surendrakumar Satyanarayan Novel pyridine derivatives
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20070522A1 (es) * 2005-09-14 2007-07-11 Takeda Pharmaceutical 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
TW200730173A (en) * 2005-12-16 2007-08-16 Sankyo Co Pharmaceutical composition enhancing production of adiponectin
JP5269758B2 (ja) 2006-03-16 2013-08-21 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 代謝性炎症によって媒介される疾患を処置するためのチアゾリジンジオン類似体
AU2007227552A1 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
CN101454006B (zh) * 2006-03-16 2012-12-26 新陈代谢解决方案开发公司 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
CA2654661C (en) 2006-06-26 2012-10-23 Amgen Inc. Compositions comprising modified lcat and use thereof for treating atherosclerosis
KR100791399B1 (ko) 2006-09-06 2008-01-07 동우신테크 주식회사 염산 피오글리타존의 제조방법
EP2213289A1 (en) 2006-09-07 2010-08-04 Nycomed GmbH Combination treatment for diabetes mellitus
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20100098641A1 (en) * 2006-12-13 2010-04-22 William Baker Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction
WO2008075380A2 (en) * 2006-12-21 2008-06-26 Ind-Swift Laboratories Limited Process for the preparation of thiazolidine derivatives
US20080176905A1 (en) * 2007-01-22 2008-07-24 Santiago Ini Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
AR065097A1 (es) * 2007-02-01 2009-05-13 Takeda Pharmaceutical Preparacion solida
EP1988091B1 (en) 2007-02-07 2015-06-10 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
WO2008105326A1 (ja) * 2007-02-28 2008-09-04 Ohara Chemical Industries, Ltd. ２－イミノ－４－チアゾリジノン誘導体及び２，４－チアゾリジンジオン誘導体の製造方法
WO2008112166A2 (en) 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN101711107A (zh) 2007-04-11 2010-05-19 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP5508258B2 (ja) 2007-06-04 2014-05-28 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ トリアリール化合物および前記化合物を含む組成物
ES2559353T3 (es) 2007-07-26 2016-02-11 Amgen, Inc Enzimas lecitina-colesterol aciltransferasa modificadas
US20110112069A1 (en) * 2007-08-17 2011-05-12 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US7960376B2 (en) * 2007-09-14 2011-06-14 Cara Therapeutics, Inc. Benzo-fused heterocycles
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
BRPI0817096B8 (pt) 2007-09-14 2021-05-25 Cirius Therapeutics Inc análogo de tiazolidinodiona e composição farmacêutica que o compreende
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
RU2366421C2 (ru) * 2007-11-01 2009-09-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав для лечения диабета
US20090118514A1 (en) * 2007-11-06 2009-05-07 Raghupathi Reddy Anumula Processes for preparing pioglitazone and its pharmaceutically acceptable salts
JP5334422B2 (ja) * 2008-02-13 2013-11-06 株式会社トクヤマ ５−｛４−［２−（５−エチル−２−ピリジル）エトキシ］ベンジル｝−２−イミノ−４−チアゾリジノンの製造方法
JP5197063B2 (ja) * 2008-02-21 2013-05-15 株式会社トクヤマ ２−ブロモ−３−｛４−［２−（５−エチル−２−ピリジル）エトキシ］フェニル｝プロピオン酸メチルの製造方法
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20110046382A1 (en) * 2008-04-28 2011-02-24 Erregierre S.P.A. Process for the preparation of 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene and pioglitazone
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US8486980B2 (en) 2008-08-06 2013-07-16 Kyowa Hakko Kirin Co., Ltd. Tricyclic compound
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
WO2010019550A2 (en) * 2008-08-12 2010-02-18 Shiraz Pharmaceuticals, Inc. Method of identifying disease risk factors
KR101791403B1 (ko) * 2008-08-15 2017-10-30 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 퓨린 유도체
WO2010026882A1 (ja) * 2008-09-02 2010-03-11 株式会社トクヤマ 脱臭化水素化抑制剤
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
WO2010041538A1 (ja) * 2008-10-10 2010-04-15 株式会社トクヤマ カルボニルオキシ化合物の製造方法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP5473303B2 (ja) * 2008-12-01 2014-04-16 株式会社トクヤマ ２−ブロモ−３−｛４−［２−（５−エチル−２−ピリジル）エトキシ］フェニル｝プロピオン酸メチルの製造方法
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
WO2010084638A1 (ja) * 2009-01-20 2010-07-29 株式会社トクヤマ ２－ブロモ－３－｛４－［２－（５－エチル－２－ピリジル）エトキシ］フェニル｝プロピオン酸メチルの脱臭化水素化を抑制する方法
JP2010208957A (ja) * 2009-03-06 2010-09-24 Tokuyama Corp 結晶構造を有する５−｛４−［２−（５−エチル−２−ピリジル）エトキシ］ベンジル｝−２−イミノ−４−チアゾリジノン及びその製造方法
MX2011009384A (es) 2009-03-11 2011-10-11 Omeros Corp Composiciones y metodos para profilaxis y tratamiento de adicciones.
NZ597108A (en) 2009-06-25 2014-04-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
MX2012005500A (es) 2009-11-13 2012-08-03 Toray Industries Agente terapeutico o profilactico para diabetes.
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
NO2513070T3 (enExample) 2009-12-15 2018-04-07
JP2013520162A (ja) 2010-01-22 2013-06-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 代謝障害の同定、査定、予防および治療のための組成物、キットおよび方法
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
JP2013538807A (ja) 2010-09-01 2013-10-17 ルピン・リミテッド メトホルミンおよびピオグリタゾンを含む医薬組成物
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PH12013501450A1 (en) 2011-01-10 2013-08-28 Takeda Pharmaceuticals Co Methods and drug products for treating alzheimer`s diseases
WO2012153312A1 (en) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Process for the purification of pioglitazone
DK3517539T3 (en) 2011-07-15 2023-01-16 Boehringer Ingelheim Int Farmaceutiske sammensætninger til behandling af type i og type ii diabetes
US8969345B2 (en) 2011-08-03 2015-03-03 Kyowa Hakko Kirin Co., Ltd. Dibenzooxepin derivative
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
CA2858787C (en) 2011-12-15 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of tertiary amine compounds
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2638898A1 (en) 2012-03-16 2013-09-18 Sanovel Ilac Sanayi ve Ticaret A.S. Metformin and Pioglitazone Formulation with Different Release Profiles
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9623015B2 (en) 2012-11-05 2017-04-18 Commissariat À L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a STAT5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
EP2968298B1 (en) 2013-03-14 2018-01-31 Deuterx, LLC Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
WO2014150512A1 (en) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Method and products for treating diabetes
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
US9815777B2 (en) 2013-09-22 2017-11-14 Jiva Pharma, Inc. Metformin salts to treat Type2 diabetes
CA2926685A1 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
AU2014347668A1 (en) 2013-11-05 2016-05-19 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
KR101606547B1 (ko) * 2014-06-02 2016-03-28 김동연 공항 탑승객 위치조회시스템
JP6702962B2 (ja) 2014-10-24 2020-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ｆｇｆ−２１ポリペプチドおよびその使用
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
MA39929A (fr) 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret As Comprimé multicouche comprenant de la metformine et du pioglitazone
BR112018075135A2 (pt) 2016-06-08 2019-03-26 Support Venture Gmbh combinações farmacêuticas para tratar câncer
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
MX2019001819A (es) 2016-08-17 2019-06-13 Support Venture Gmbh Metodo para prevenir o tratar la perdida de la audicion.
TR201620309A2 (tr) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
EP3606514A1 (en) 2017-04-04 2020-02-12 Strekin AG Methods of preventing or treating ophthalmic diseases
WO2019154893A1 (en) 2018-02-08 2019-08-15 Strekin Ag Oral extended release pharmaceutical compositions for preventing or treating hearing loss
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US20210267983A1 (en) 2018-07-13 2021-09-02 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
CN111875598B (zh) * 2020-05-23 2023-10-10 白银京宇新药业有限公司 一种吡格亚胺的制备方法
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
WO2022034031A1 (en) 2020-08-11 2022-02-17 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders
KR20230079085A (ko) 2020-09-30 2023-06-05 듀얼리티 바이올로직스 (쑤저우) 컴퍼니 리미티드 항종양 화합물 및 그의 제조 방법 및 용도
JP6925072B1 (ja) * 2020-12-07 2021-08-25 株式会社Dr.Cherry 毛髪改善のための組成物
EP4385502A1 (en) 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor
EP4385501A1 (en) 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A pharmaceutical formulation comprising linagliptin, pioglitazone and a sglt-2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途

Also Published As

Publication number Publication date
CN1003934B (zh) 1989-04-19
FI81098B (fi) 1990-05-31
HUT41775A (en) 1987-05-28
DE10199018I1 (de) 2001-07-12
CN86100411A (zh) 1986-07-16
FI81098C (fi) 1990-09-10
ZA86203B (en) 1987-09-30
AU5246786A (en) 1986-07-24
AR240698A1 (es) 1990-09-28
NO163857C (no) 1990-08-01
JPH0566956B2 (enExample) 1993-09-22
NO860141L (no) 1986-07-21
LV5779A4 (lv) 1996-12-20
ATE41931T1 (de) 1989-04-15
ES550986A0 (es) 1987-05-16
GR860124B (en) 1986-05-19
JPS61267580A (ja) 1986-11-27
IE860107L (en) 1986-07-19
MX9202933A (es) 1992-06-30
PT81859A (en) 1986-02-01
EP0193256A1 (en) 1986-09-03
DE10199018I2 (de) 2006-02-02
LV5779B4 (lv) 1997-04-20
LU90719I2 (fr) 2001-03-26
SG105691G (en) 1992-02-14
ES8705886A1 (es) 1987-05-16
HK3692A (en) 1992-01-17
MY102016A (en) 1992-02-29
US4687777A (en) 1987-08-18
FI860232L (fi) 1986-07-20
KR860005811A (ko) 1986-08-13
IE58928B1 (en) 1993-12-01
HU196795B (en) 1989-01-30
NO163857B (no) 1990-04-23
DK21986A (da) 1986-07-20
NL300038I2 (nl) 2001-05-01
FI860232A0 (fi) 1986-01-17
AU572719B2 (en) 1988-05-12
EP0193256B1 (en) 1989-04-05
DK171614B1 (da) 1997-02-24
CS407991A3 (en) 1992-04-15
BR1100325A (pt) 2000-06-27
CA1277323C (en) 1990-12-04
PT81859B (pt) 1988-05-27
DK21986D0 (da) 1986-01-17
KR920010046B1 (ko) 1992-11-13

Similar Documents

Publication Publication Date Title
DE3662689D1 (en) Thiazolidinedione derivatives, their production and use
EP0207581A3 (en) Thiazolidine derivatives, their preparation and use
EP0196096A3 (en) Imide derivatives, their production and use
GB2177395B (en) Thiazoles, their production and pharmaceutical compositions containing them
EP0149884A3 (en) 5-pyridyl-1,3-thiazole derivatives, their production and use
EP0202589A3 (en) Ascorbic acid derivatives, production and use thereof
AU8304087A (en) Coumarane derivatives, their production and use
DE3262455D1 (en) Diphenoxypropane derivatives, their production and use
EP0186190A3 (en) Benzimidazole derivatives, and their production and use
AU586034B2 (en) Benzothiazolones, and their production and use
IL87189A0 (en) Pyridinium derivatives,their production and use
PT84704A (en) Thiolactam-n-acetic derivatives their production and use
DE3568435D1 (en) 2-acetoacetylglycerol derivatives, their production and use
EP0260121A3 (en) Inosose derivatives, production and use thereof
DE3663522D1 (en) Phospholipid derivatives, their production and use
GR3003110T3 (en) Inosose derivatives and production thereof
ZA866529B (en) Azolyl-cyclopropyl-ethanol derivatives,processes for their preparation and their use
IL74133A0 (en) Azolyl-aryl-alkanol derivatives,processes for their preparation and their use
ZA857448B (en) Thiazolidinedione derivatives,their production and use
GB8925439D0 (en) Adenosin derivatives,their production and use
EP0188259A3 (en) Benzotriazoles, and their production and use
GB2181729B (en) Glucosylmoranoline derivatives and production thereof
ZA857272B (en) Vinyltetrazolylphenyl derivatives,their preparation and their use
ZA895305B (en) Quinoline derivatives,their production and use
EP0271829A3 (en) Delta-hydroxy-beta-lysine derivatives and their production

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: GLUSTIN PIOGLITAZONE; REGISTRATION NO/DATE: EU/1/00/151/001 - EU/1/00/151/006; 20001011

Spc suppl protection certif: 101 99 018

Filing date: 20010310

V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: GLUSTIN PIOGLITAZONE; REGISTRATION NO/DATE: EU/1/00/151/001 - EU/1/00/151/006; 20001011

Spc suppl protection certif: 101 99 018

Filing date: 20010310

V457 Spc granted

Free format text: PRODUCT NAME: GLUSTIN PIOGLITAZONE; REGISTRATION NO/DATE: EU/1/00/151/001 - EU/1/00/151/006; 20001011

Spc suppl protection certif: 101 99 018

Filing date: 20010310

V464 Spc expired

Free format text: PRODUCT NAME: GLUSTIN PIOGLITAZONE; REGISTRATION NO/DATE: EU/1/00/151/001 - EU/1/00/151/006; 20001011

Spc suppl protection certif: 101 99 018

Filing date: 20010310